Samsung Biologics disclosed on October 21, 2026 that it revised its consolidated revenue outlook for 2026 upward, from KRW 5.32 trillion to KRW 5.4684 trillion.

Samsung Biologics said in its October 21, 2026 filing that it revised its consolidated revenue outlook for 2026 upward. The revised revenue outlook for 2026 that the company presented is 54,684 (in the units used in the original filing), and the company said it calculated this amount on the basis of an expected revenue growth rate of +20% year on year. The company said this information is forward-looking and that actual results may differ depending on business conditions or market conditions.

1. 01

   The reason for the revision was an upward revision to the revenue outlook, and the consolidated revenue outlook for 2026 changed from 53,200 to 54,684.

2. 02

   The company said the 2026 revenue was calculated on the basis of the expected revenue growth rate of +20% year on year.

3. 03

   The revenue outlook for 2025 was KRW 5.7978 trillion, while actual revenue came in at KRW 4.557 trillion, an error rate of -21.4%.

4. 04

   The company said the outlook included Samsung Bioepis, which was announced before the spin-off, while the actual results are on a basis that excludes Samsung Bioepis after the spin-off.

An AI model translated the Korean summary of this filing into English; every number is carried over from the Korean original. Reference information, not investment advice.

Key figures

2026 revenue outlook (revised)

KRW 5.4684 trillion

2026 revenue outlook (original)

53,200

2025 revenue (actual)

KRW 4.557 trillion

Error rate versus 2025 revenue outlook

-21.4%

Filing facts

Filing type

Earnings Outlook

Report name

[Amended] Consolidated Operating Results Outlook (Fair Disclosure)

Filed

Oct 21, 2026

Receipt number

20261021800395